Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
|Videos|September 26, 2022
Dr. Gupta on safety and sequencing of antibody-drug conjugates in urothelial cancer
Author(s)Urology Times staff
Advertisement
Shilpa Gupta, MD, director of Genitourinary Oncology at Cleveland Clinic compares the safety profile of the antibody-drug conjugates (ADCs) sacituzumab govitecan (Trodelvy) and enfortumab vedotin (Padcev). Both ADCs are FDA-approved for the treatment of patients with locally advanced or metastatic urothelial cancer previously treated with chemotherapy and a PD-1/PD-L1 inhibitor.
Advertisement
Related to this article
Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Mark D. Tyson II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Butterfly Prostatic Retraction Device granted EU MDR certification for BPH
3
Matching mCSPC treatment to the patient, not just the trial data
4
Timothy Clinton, MD, reviews bladder cancer data from 2026 AUA Northeastern Section Meeting
5